OnabotulinumtoxinA,
does it really help with Temporary appearance improvement of moderate or severe glabellar expression lines?
research showsOnabotulinumtoxinA 20 U clearly improves moderate or severe glabellar expression lines versus placebo, but it is rated C. Carruthers 2002 randomized and analyzed all 264 participants by intention to treat; physician-rated severity at maximum frown and patient global assessment were better than placebo at every follow-up, so the primary efficacy outcome succeeded. A separate 273-patient trial reproduced day-30 physician response of 77% and patient response of 89%. Both pivotal trials, however, were Allergan-funded product-development studies with company employees and focused on short-term cosmetic ratings. Rule ②-b caps entirely positive evidence from manufacturer-only studies at C with 55 points.
ads claimMarketing may describe wrinkle erasure or long-term age reversal, but the procedure temporarily reduces muscle contraction and softens the appearance of expression lines. It does not reverse skin aging or permanently eliminate wrinkles.
Useful facts when choosing a product
- A common labeled approach injects a total of 20 U across five sites in the corrugator and procerus muscles.
- Benefit begins within days and commonly lasts about three to four months, after which repeat treatment may be sought.
- Headache, injection-site pain, bruising, eyelid ptosis, and eyebrow asymmetry can occur.
- Potency units are not interchangeable across botulinum toxin products; authentic product, dilution, and anatomical placement matter.
Chamgap Semantic Classification Code
Candidate index · review held
M.onabotulinumtoxina-injections-into-the-glabellar-muscles.intramuscular.temporary-appearance-improvement-of-moderate-or-severe-glabellar-expression-lines.improve.placeboMedicinal interventions > OnabotulinumtoxinA injections into the glabellar muscles > Intramuscular > Temporary appearance improvement of moderate or severe glabellar expression lines > Improvement claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Carruthers et al. 2002 (J Am Acad Dermatol 46(6):840-849) randomized 264 participants, 203 Botox and 61 placebo, and analyzed all 264 by intention to treat. Physician-rated severity at maximum frown and patient global assessment improved significantly at every follow-up. Allergan, Inc. funded the trial and several coauthors were employees. Carruthers et al. 2003 randomized 273 participants and also reported positive ratings. Appearance is itself the treatment goal in a cosmetic indication, but assessment is subjective and the evidence is concentrated in Allergan studies, supporting C. This indication differs from verdict 1694, which is C with 55 points, verdict 1705, which is C with 45 points, and verdict 1733, which is C with 59 points, so their evidence was not imported.
Why this is classified as C (55)
Direct cosmetic efficacy succeeded repeatedly in the 264-patient intention-to-treat trial and the 273-patient follow-up trial. Both pivotal studies were concentrated in Allergan-funded programs with employee involvement and lacked independent nonindustry placebo-controlled replication, so rule ②-b caps the grade at C with 55 points.
Counterpoint. Efficacy is convincing for the narrow goal of temporary glabellar-line softening, but it should not be interpreted as permanent wrinkle removal or global skin rejuvenation.
Rejudgment record. Cross-check applied — Carruthers 2002 (J Am Acad Dermatol 46(6):840-849) randomized and analyzed 264 participants and was funded by Allergan, Inc. Appearance is itself the treatment goal in a cosmetic indication, but assessment is subjective and the evidence is concentrated in Allergan studies, so the rule ②-b ceiling of C applies.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement of moderate or severe glabellar lines at maximum frown | C | Large responses were repeated in two placebo-controlled trials, but both came from the same manufacturer program. |
| Patient-perceived improvement in glabellar appearance | C | Day-30 patient response reached 89%, but independent nonindustry replication is absent. |
| Temporary benefit lasting about three to four months | C | A signal persisted to day 120, but this is not evidence of permanent wrinkle improvement. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Carruthers JA et al. 2002 | Multicenter randomized double-blind placebo-controlled trial | 264 randomized and analyzed by intention to treat, 203 onabotulinumtoxinA and 61 placebo | Funded by Allergan Inc.; several coauthors were company employees | Physician-rated glabellar-line severity at maximum frown and patient global assessment | Primary efficacy outcome succeeded: treatment was significantly superior at every follow-up, all comparisons P<0.022. | Key direct cosmetic-efficacy randomized trial |
| Carruthers JD et al. 2003 | Randomized double-blind placebo-controlled trial | 273 randomized and included in efficacy analysis, 202 versus 71; 268 completed | Allergan Inc. product-development study with company-employee coauthors | Physician severity response at maximum frown and patient global assessment | Primary efficacy result succeeded: day-30 physician response 77% and patient response 89%; P<0.001 versus placebo at every visit. | Same-manufacturer replication |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] OnabotulinumtoxinA x improvement of glabellar expression lines — Evidence Grade C·55. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/antioxidant-aging/onabotulinumtoxin-a-moderate-severe-glabellar-lines/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.